RTP Mobile Logo
Prostate Cancer Update, Issue 1, 2021 (Audio Program)
Released January 2021

Featuring perspectives from Drs Philip Kantoff and Fred Saad. (Audio Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

    OVERVIEW OF ACTIVITY
    Cancers of the genitourinary system affect hundreds of thousands of individuals within the United States each year and comprise more than one fourth of all newly diagnosed human cancer cases. Of this diverse array of distinct diseases, tumors of the prostate are among the most prevalent and thus the focus of extensive ongoing clinical research. A result of this research is that the clinical management of both early and more advanced presentations of prostate cancer is constantly evolving, necessitating rapid and consistent access to learning opportunities for clinicians.

    To provide clinicians with therapeutic strategies to address the needs of patients with prostate cancer, this program, developed in partnership with the University of South Florida (USF Health) Office of Continuing Professional Development, features presentations and one-on-one discussions with leading clinical investigators. By providing expert perspectives on the latest developments, this activity will assist medical oncologists with the formulation of evidence-based and current therapeutic strategies, which in turn will facilitate optimal patient care.

    LEARNING OBJECTIVES

    • Appraise the published research database supporting approved and investigational secondary hormonal agents in the management of nonmetastatic prostate cancer, and consider this information in the discussion of treatment options for patients.
    • Recall available data on the use of cytotoxic and secondary hormonal therapy in the setting of metastatic hormone-sensitive prostate cancer to design effective treatment plans for patients.
    • Recognize how prior therapeutic exposure and other patient and disease characteristics factor into the selection and sequencing of available systemic treatments for metastatic castration-resistant prostate cancer (CRPC).
    • Understand the rationale for testing patients with metastatic prostate cancer for DNA damage repair alterations, including BRCA1/2 mutations, and advise individuals found to harbor these genetic abnormalities about the availability of PARP inhibitor-based therapies in or outside of a clinical trial setting.
    • Recall the design of ongoing research studies evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.
    • Educate patients about the side effects associated with approved therapies commonly employed in the management of advanced prostate cancer, and provide preventive strategies to reduce or ameliorate these toxicities.

    COMPETENCIES TO BE ADDRESSED
    Patient Care and Procedural Skills and Medical Knowledge.

    CONTACT INFORMATION
    If you have questions regarding credit, please contact cpdsupport@usf.edu.

    ACCREDITATION STATEMENT
    USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health and Research To Practice that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Philip Kantoff, MD
    Chairman of Medicine
    Memorial Sloan Kettering Cancer Center
    Professor of Medicine
    Weill Cornell Medical School
    George J Bosl Professor of Medicine
    New York, New York

    Advisory Committee and Consulting Agreements: Bavarian Nordic, Druggability Technologies Holdings Ltd, GE Healthcare, Immunis.AI, Janssen Biotech Inc, Progenity, Seer Biosciences, SynDevRx Inc, Tarveda Therapeutics; Data and Safety Monitoring Board/Committee: Genentech, a member of the Roche Group, Merck; Ownership Interest: Cogent Biosciences, Context Therapeutics, Druggability Technologies Holdings Ltd, Mirati Therapeutics, Placon Therapeutics, Seer Biosciences, Xlink; Other: Board Member, Context Therapeutics; Founder, Xlink.

    Fred Saad, MD
    Professor and Chief of Urology
    Director of GU Oncology
    Raymond Garneau Chair in Prostate Cancer
    University of Montreal Hospital Center (CHUM)
    Director, Prostate Cancer Research
    Montreal Cancer Institute/CRCHUM
    Montréal, Québec

    Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    USF HEALTH CPD STAFF AND RESEARCH TO PRACTICE CME PLANNING COMMITTEE — Members, Staff, and Reviewers have no relevant conflicts to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals Inc, Clovis Oncology Inc, Merck, and Sanofi Genzyme.

    Release date: January 2021
    Expiration date: January 2022

Acknowledge and close

Listen to audio
(WIFI is recommended for best performance):

Presentation and Interview
with Fred Saad, MD

Presentation and Interview
with Philip Kantoff, MD